Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (10): 608-613.doi: 10.3760/cma.j.cn371439-20230328-00115
• Original Articles • Previous Articles Next Articles
Kui Guoju1, Huang Jiangbin1, Zhang Wenhua2, Yang Limin1()
Received:
2023-03-28
Revised:
2023-06-20
Online:
2023-10-08
Published:
2023-11-08
Contact:
Yang Limin
E-mail:ylm013@163.com
Kui Guoju, Huang Jiangbin, Zhang Wenhua, Yang Limin. Effect of regional lymph node diameter on postoperative recurrence in pancreatic cancer patients[J]. Journal of International Oncology, 2023, 50(10): 608-613.
"
项目 | 例数 | 淋巴结平均直径(cm) | t值 | P值 |
---|---|---|---|---|
年龄(岁) | ||||
<50 | 15 | 0.62±0.11 | 0.36 | 0.719 |
≥50 | 34 | 0.61±0.09 | ||
性别 | ||||
女 | 21 | 0.64±0.09 | 1.47 | 0.150 |
男 | 28 | 0.59±0.10 | ||
BMI(kg/m2) | ||||
<24 | 42 | 0.63±0.12 | 0.84 | 0.427 |
≥24 | 7 | 0.60±0.08 | ||
糖尿病史 | ||||
无 | 35 | 0.62±0.10 | 0.56 | 0.579 |
有 | 14 | 0.60±0.10 | ||
吸烟史 | ||||
无 | 37 | 0.62±0.10 | 0.01 | 0.921 |
有 | 12 | 0.61±0.10 | ||
肿瘤直径(cm) | ||||
<2 | 24 | 0.58±0.11 | -2.12 | 0.040 |
≥2 | 25 | 0.64±0.08 | ||
肿瘤分期 | ||||
Ⅰ | 34 | 0.59±0.10 | -1.69 | 0.097 |
Ⅱ | 15 | 0.65±0.08 | ||
肿瘤分化 | ||||
高分化 | 24 | 0.59±0.09 | -2.24 | 0.013 |
中低分化 | 25 | 0.65±0.10 | ||
脉管侵犯 | ||||
无 | 37 | 0.58±0.09 | -3.47 | 0.001 |
有 | 12 | 0.69±0.07 | ||
神经侵犯 | ||||
无 | 38 | 0.56±0.10 | -3.75 | <0.001 |
有 | 11 | 0.67±0.10 | ||
被膜侵犯 | ||||
无 | 32 | 0.56±0.10 | -4.25 | <0.001 |
有 | 17 | 0.67±0.08 | ||
淋巴结个数(个) | ||||
<17 | 22 | 0.63±0.06 | 0.86 | 0.413 |
≥17 | 27 | 0.60±0.07 | ||
肿瘤复发 | ||||
无 | 20 | 0.54±0.08 | -4.42 | <0.001 |
有 | 29 | 0.66±0.08 |
"
因素 | 无复发组 (n=20) | 复发组 (n=29) | χ2值 | P值 | 因素 | 无复发组 (n=20) | 复发组 (n=29) | χ2值 | P值 | |
---|---|---|---|---|---|---|---|---|---|---|
年龄(岁) | 肿瘤分化 | |||||||||
<50 | 5 | 10 | 0.50 | 0.479 | 高分化 | 14 | 10 | 5.98 | 0.015 | |
≥50 | 15 | 19 | 中低分化 | 6 | 19 | |||||
性别 | 脉管侵犯 | |||||||||
女 | 8 | 13 | 0.11 | 0.737 | 无 | 18 | 19 | 3.84 | 0.050 | |
男 | 12 | 16 | 有 | 2 | 10 | |||||
BMI(kg/m2) | 神经侵犯 | |||||||||
<24 | 17 | 25 | <0.01 | >0.999 | 无 | 17 | 21 | 0.48 | 0.491 | |
≥24 | 3 | 4 | 有 | 3 | 8 | |||||
糖尿病史 | 被膜侵犯 | |||||||||
无 | 14 | 21 | 0.03 | 0.854 | 无 | 17 | 15 | 5.79 | 0.016 | |
有 | 6 | 8 | 有 | 3 | 14 | |||||
吸烟史 | 淋巴结个数(个) | |||||||||
无 | 15 | 22 | <0.01 | >0.999 | <17 | 11 | 11 | 1.39 | 0.238 | |
有 | 5 | 7 | ≥17 | 9 | 18 | |||||
肿瘤直径(cm) | 淋巴结平均直径(cm) | |||||||||
<2 | 14 | 10 | 5.98 | 0.015 | <0.635 | 17 | 8 | 15.61 | <0.001 | |
≥2 | 6 | 19 | ≥0.635 | 3 | 21 | |||||
肿瘤分期 | 术后化疗 | |||||||||
Ⅰ | 17 | 17 | 3.88 | 0.049 | 是 | 17 | 17 | 3.89 | 0.049 | |
Ⅱ | 3 | 12 | 否 | 3 | 12 |
"
因素 | β值 | SE值 | Wald χ2值 | OR值 | 95%CI | P值 |
---|---|---|---|---|---|---|
肿瘤直径(<2 cm为对照) | 1.821 | 0.818 | 1.684 | 2.72 | 1.46~11.28 | 0.016 |
肿瘤分期(Ⅰ期为对照) | 0.096 | 1.001 | 0.039 | 1.10 | 0.16~7.83 | 0.623 |
肿瘤分化(高分化为对照) | 1.195 | 0.857 | 1.552 | 2.22 | 1.23~6.53 | 0.020 |
被膜侵犯(无为对照) | 1.262 | 0.891 | 1.373 | 2.30 | 2.19~8.91 | 0.017 |
淋巴结平均直径(<0.635 cm为对照) | 2.070 | 0.943 | 4.821 | 7.93 | 1.25~50.31 | 0.002 |
术后化疗(否为对照) | 0.537 | 0.947 | 0.322 | 0.58 | 0.09~3.74 | 0.570 |
[1] | 国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5): 1006-1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007. |
[2] | 中国医师协会放射肿瘤治疗医师分会. 胰腺癌立体定向放疗(放射外科)指南[J]. 国际肿瘤学杂志, 2021, 48(11): 643-648. DOI: 10.3760/cma.j.cn371439-20210621-00128. |
[3] |
Javadi S, Karbasian N, Bhosale P, et al. Imaging findings of recurrent pancreatic cancer following resection[J]. Abdom Radiol (NY), 2018, 43(2): 489-496. DOI: 10.1007/s00261-017-1397-8.
pmid: 29198001 |
[4] | Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X. |
[5] |
Rocha FG. Landmark series: immunotherapy and targeted therapy for pancreatic cancer[J]. Ann Surg Oncol, 2021, 28(3): 1400-1406. DOI: 10.1245/s10434-020-09367-9.
pmid: 33386541 |
[6] | Zhou CF, Ma J, Huang L, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1[J]. Oncogene, 2019, 38(8): 1256-1268. DOI: 10.1038/s41388-018-0511-x. |
[7] |
Kim H, Kwon W, Kim JR, et al. Recurrence patterns after pancreaticoduodenectomy for ampullary cancer[J]. J Hepatobiliary Pancreat Sci, 2019, 26(5): 179-186. DOI: 10.1002/jhbp.618.
pmid: 30849209 |
[8] |
Agalar C, Aysal A, Unek T, et al. The role of log odds of positive lymph nodes in predicting the survival after resection for ampullary adenocarcinoma[J]. Pathol Oncol Res, 2020, 26(1): 467-473. DOI: 10.1007/s12253-019-00584-6.
pmid: 30693420 |
[9] | Jang JY, Kang JS, Han Y, et al. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study[J]. J Hepatobiliary Pancreat Sci, 2017, 24(7): 426-433. DOI: 10.1002/jhbp.465. |
[10] | 徐业成, 傅德良. 胰腺癌淋巴结转移研究进展[J]. 肝胆外科杂志, 2022, 30(1): 76-80. DOI: 10.3969/j.issn.1006-4761.2022.01.022. |
[11] | Pedrazzoli S. Surgical treatment of pancreatic cancer: currently debated topics on morbidity, mortality, and lymphadenectomy[J]. Surg Oncol, 2022, 45: 101858. DOI: 10.1016/j.suronc.2022.101858. |
[12] |
Ignjatovic I, Knezevic S, Knezevic D, et al. Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma[J]. J BUON, 2017, 22(1): 232-238.
pmid: 28365959 |
[13] | Warschkow R, Tsai C, Köhn N, et al. Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer — a distinct view on lymph node yield[J]. Langenbecks Arch Surg, 2020, 405(1): 43-54. DOI: 10.1007/s00423-020-01859-2. |
[14] |
Lino-Silva LS, Salcedo-Hernández RA, Segales-Rojas P, et al. Comparison of 3 ways of dissecting the pancreatoduodenectomy specimen and their impact in the lymph node count and the lymph node metastatic ratio[J]. Int J Surg Pathol, 2018, 26(8): 707-713. DOI: 10.1177/1066896918780343.
pmid: 29873282 |
[15] | Kado T, Tomimaru Y, Kobayashi S, et al. Prognostic impact of gastroduodenal artery involvement in cancer of the pancreatic head[J]. Ann Surg Oncol, 2023, 30(4): 2413-2421. DOI: 10.1245/s10434-022-12759-8. |
[16] | Lu Y, Jiang J, Ren C. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: a meta-analysis[J]. PLoS One, 2020, 15(4): e0230979. DOI: 10.1371/journal.pone.0230979. |
[17] |
Velazquez-Caldelas TE, Alcalá-Corona SA, Espinal-Enríquez J, et al. Unveiling the link between inflammation and adaptive immunity in breast cancer[J]. Front Immunol, 2019, 10: 56. DOI: 10.3389/fimmu.2019.00056.
pmid: 30761130 |
[18] |
Tang J, Yang Z, Wang Z, et al. Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer[J]. World J Surg Oncol, 2017, 15(1): 173. DOI: 10.1186/s12957-017-1221-5.
pmid: 28923073 |
[19] | Luchini C, Veronese N, Nottegar A, et al. Perineural invasion is a strong prognostic moderator in ampulla of vater carcinoma: a meta-analysis[J]. Pancreas, 2019, 48(1): 70-76. DOI: 10.1097/MPA.0000000000001194. |
[20] | El Nakeeb A, El Sorogy M, Ezzat H, et al. Predictors of long-term survival after pancreaticoduodenectomy for peri-ampullary adenocarcinoma: a retrospective study of 5-year survivors[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(5): 443-449. DOI: 10.1016/j.hbpd.2018.08.004. |
[21] | 王媛媛, 蒙博, 王莹莹. 影响胰腺癌切除术后患者预后的相关危险因素分析[J]. 实用癌症杂志, 2023, 38(1): 142-144, 151. DOI: 10.3969/j.issn.1001-5930.2023.01.041. |
[22] | 保吉红, 海华, 党雅莹. 胰头癌患者胰十二指肠切除术后复发的危险因素[J]. 实用癌症杂志, 2022, 37(6): 968-970. DOI: 10.3969/j.issn.1001-5930.2022.06.028. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[7] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[12] | Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[13] | Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64. |
[14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469. |
[15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||